首页> 美国卫生研究院文献>Human Vaccines Immunotherapeutics >Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen)
【2h】

Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen)

机译:根据两种不同的模拟暴露后肌肉注射方案(萨格勒布与埃森)施用纯化的鸡胚狂犬病狂犬病疫苗(PCECV)的免疫原性和安全性的比较研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite availability of effective rabies vaccines, India has the highest global mortality rate for rabies. Low socio-economic communities are most affected due to lack of awareness of the disease and poor compliance to post-exposure prophylactic regimens. Currently, the only approved intramuscular regimen for post-exposure prophylaxis (PEP) against rabies in India is the Essen regimen, which consists of 5 injections administered over 5 separate days in a period of one month. The high number of doses and clinical visits, however, are major reasons for non-compliance, and thus a shorter regimen would be beneficial. In a simulated PEP trial in healthy, adult subjects, this study evaluated whether purified chick embryo cell vaccine (PCECV), administered according to the WHO-recommended 4-dose/3 visit Zagreb vaccination regimen is of equal immunogenicity and safety as the standard Essen regimen in Indian subjects. Two hundred and 50 healthy adults were enrolled and randomized into a Zagreb or Essen group, each receiving PCECV according to their respective regimen. Blood samples were collected on Days 0, 7, 14 and 42 and analyzed using the rapid fluorescent focus inhibition test (RFFIT). By Day 14, all subjects across both groups attained rabies virus neutralizing antibody (RVNA) concentrations of ≥ 0.5IU/ml. The Zagreb regimen was then demonstrated to be immunologically non-inferior to the Essen regimen by Day 14, which was the primary endpoint of the study. No safety issues were noted and the occurrence of adverse events was similar in both groups (17% and 15%, respectively). . CTRI No.: CTRI/2011/07/001857
机译:尽管可获得有效的狂犬病疫苗,但印度的狂犬病全球死亡率最高。由于对疾病的了解不足以及对接触后预防方案的依从性差,低社会经济社区受到的影响最大。目前,印度唯一批准的针对狂犬病的暴露后预防(PEP)的肌肉内治疗方案是Essen方案,该方案由5个注射液组成,每个注射液在5天内分5天进行。但是,高剂量和临床就诊是不依从的主要原因,因此缩短疗程将是有益的。在一项针对健康,成年受试者的模拟PEP试验中,该研究评估了按照WHO建议的4剂量/ 3访萨格勒布疫苗接种方案施用的纯化鸡胚细胞疫苗(PCECV)的免疫原性和安全性是否与标准埃森疫苗相同印度受试者的养生方法。招募了250名健康成年人并随机分为Zagreb或Essen组,每人均根据各自的方案接受PCECV。在第0、7、14和42天收集血样,并使用快速荧光聚焦抑制测试(RFFIT)进行分析。到第14天,两组的所有受试者均达到≥0.5IU / ml的狂犬病毒中和抗体(RVNA)浓度。然后,在第14天,即研究的主要终点,证明了Zagreb方案在免疫学上不逊于Essen方案。两组均未发现安全问题,不良事件的发生率相似(分别为17%和15%)。 。 CTRI编号:CTRI / 2011/07/001857

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号